Dr. Michael Wang is a pediatric hematologist dedicated to advancing clinical coagulation by leading a multidisciplinary team focusing our advancing knowledge and innovation on caring for patients with bleeding and clotting disorders. He completed medical training at the University of Rochester, residency at the University of Utah, and fellowship at the University of Colorado, where is currently a faculty member in the Department of Pediatrics. As Clinical Director of the University of Colorado Hemophilia & Thrombosis Center (HTC), he combines clinical care, health care delivery improvement, patient engagement, clinical trials, and teaching, to improve the lives of our patients throughout their entire lifespan. The University of Colorado HTC has an established clinical research program that spans the breadth of local, national and international investigator-initiated research, national and international disease-specific registries, local and national patient reported outcome trials, and leadership in industry-sponsored multicenter Phase I-IV clinical trials evaluating both pro- and anti-coagulant strategies and patient reported clinical outcomes. The recent success and approval of multiple new treatments in hemostasis and thrombosis has led to a re-focusing on how patient care is being delivered. Dr. Wang and his team have embraced the challenge of translating the use of novel medicines into clinical care while striving to improve clinical outcomes through continued clinical investigation.